Changing Trends of Cirrhotic and Noncirrhotic Hepatocellular Carcinoma in the Era of Directly-Acting Antiviral Agents

Karan Mathur, MD1, Areej Mazhar, MD2, Milin Patel, MD2, Lara Dakhoul, MD2, Heather Burney, MS4, Hao Liu, PhD4, Lauren Nephew, MD1, Naga Chalasani, MD1, Andrew deLemos, MD2 and Samer Gawrieh, MD1

INTRODUCTION: The impact of direct-acting antivirals (DAAs) for hepatitis C virus (HCV) on burden of cirrhotic and noncirrhotic hepatocellular carcinoma (HCC) has not been examined. We assessed recent trends in liver disease etiologies of HCC and proportion of noncirrhotic HCC since DAAs introduction.

METHODS: Clinical characteristics including presence or absence of underlying cirrhosis were collected from 2,623 patients diagnosed with HCC between 2009 and 2019 at 2 large US centers. Logistic regression was performed to investigate the annual trends of HCC due to different liver diseases and proportions of noncirrhotic cases.

RESULTS: In the DAA era (2014–2019), annual decline in HCV-HCC (odds ratio [OR] = 0.93, 95% confidence interval [CI] 0.88–0.99, P = 0.019), without change in trends of other liver diseases–related HCC, was observed. Annual increase in noncirrhotic HCC (OR 1.13, 95% CI 1.03–1.23, P = 0.009) and decline in cirrhotic HCC (OR 0.89, 95% CI 0.81–0.97, P = 0.009) along with similar trends for HCV-HCC—increase in noncirrhotic cases (OR 1.35, 95% CI 1.08–1.69, P = 0.009) and decrease in cirrhotic cases (OR 0.92, 95% CI 0.86–0.98, P = 0.012)—were observed during the DAA era. Compared with the pre-DAA era, HCC resection rate increased (10.7% vs 14.0%, P = 0.013) whereas liver transplantation rate decreased (15.1% vs 12.0%, P = 0.023) in the DAA era.

DISCUSSION: Since introduction of DAAs, proportions of cirrhotic HCC have decreased, whereas proportions of noncirrhotic HCC have increased. These new trends were associated with change in utilization of liver resection and transplantation for HCC. The impact of changing patterns of DAA use on these trends will require further study.

SUPPLEMENTARY MATERIAL accompanies this paper at http://links.lww.com/CTG/A715

Clinical and Translational Gastroenterology 2021;12:e00420. https://doi.org/10.14309/ctg.0000000000000420

INTRODUCTION

Hepatocellular carcinoma (HCC) is the fourth most common cause of cancer-related mortality worldwide (1). In the United States, incidence rates of HCC increased by 4.5% per year from 2000 to 2009 and then slowed down to rise 0.7% annually until the year 2012 (2). In North America, the age-standardized incidence rates of HCC have increased more than 100 percent between 1990 and 2015 (3). HCC-associated deaths are forecasted to be significantly worse in 2040 compared with 2016 (4). Chronic hepatitis C virus (HCV), chronic hepatitis B virus (HBV), and alcoholic liver disease are the most common underlying etiologies for HCC globally (1,5).

HCC secondary to HCV (HCV-HCC) occurs mostly in the background of cirrhosis (6). The introduction of direct-acting antivirals (DAAs) treatment in 2014 revolutionized the management of HCV. More than 90% of patients treated with DAA achieve sustained virological response (SVR) regardless of fibrosis stage (7). Even patients with decompensated cirrhosis have excellent SVR rates (8). Despite initial controversy, the impressive SVR rates associated with DAA seem to decrease but not completely eliminate the risk of HCV-HCC (9–12). The 2- to 3-year incidence of HCC is estimated to be 3%–4% after achieving SVR with DAA therapy (10,12). There have been concerns on whether...
DAA treatment may be a risk for development of de novo HCC after achieving SVR (13,14). However, several reports and expert consensus have demonstrated the case to be otherwise (12,15–19).

The burden of nonalcoholic fatty liver disease (NAFLD)-related HCC (NAFLD-HCC) in the United States has increased in recent years (20). In the 2004–2009 surveillance, epidemiology, and end results Medicare database study, NAFLD was the third leading cause of HCC after HCV and alcohol (21), trends that we confirmed in a recent large multicenter study (22). In addition, between 2000 and 2014, we observed an increased proportion of cirrhotic HCC and a decline in noncirrhotic HCC mainly because of significant annual increases in cirrhotic HCC due to HCV and NAFLD (22). It is unclear whether these trends have changed since the introduction of DAAs for HCV in 2014, especially with the continued rise in NAFLD burden in the United States (23). In this study, we aimed to evaluate trends of underlying liver diseases associated with HCC and underlying cirrhotic status at the time of HCC diagnosis since introduction of DAAs. We also examined whether there had been associated changes in utilization of different HCC treatment modalities in the DAA era. We used patient-level data from 2 large US centers 5 years before and 5 years after the introduction of DAA therapy.

METHODS
Patient identification and characterization
This was a retrospective study involving 2 academic tertiary care medical centers: Indiana University School of Medicine, Indianapolis, Indiana, and Atrium Health, Charlotte, North Carolina. The study protocol was approved by the Institutional Review Board of both participating sites. We addressed all the important aspects of the Strengthening the Reporting of Observational studies in Epidemiology statement guidelines (24).

Using the institutional cancer registry, patients diagnosed with HCC between January 2009 and June 2019 were identified. A manual chart review of each HCC case was completed using the electronic medical record to verify the HCC diagnosis. Confirmation of HCC diagnosis was performed either by histological or radiological evidence as per the American Association for Study of Liver Disease guidelines (25). Clinical data at the time of diagnosis, including demographics, comorbidities, date of HCC diagnosis, underlying HCC etiology, laboratory values, presence or absence of cirrhosis, method of diagnosis, and surveillance status, were collected. Histology and radiology data were used to determine tumor size, vascular invasion, staging, and Milan status. Histological grading of HCC on pathology was defined as poorly differentiated, moderately differentiated, well-differentiated, or anaplastic. The Tumor, Node, Metastasis classification was used for anatomic staging (26). We also used the Milan criteria to define the tumor burden regarding size and number of lesions (27). Clinical staging at the time of HCC diagnosis was conducted using the Barcelona Clinic Liver Cancer staging criteria (28). All treatment modalities received for HCC during the disease course were also identified. These modalities were classified as resection, liver transplantation, catheter-directed therapy, radiofrequency ablation, microwave ablation, stereotactic body radiation therapy, sorafenib, palliative/hospice care, other (systemic agents), none, and unknown. For HCV patients, data on all treatment including DAA therapy were collected. Cases were classified as DAA therapy recipients if they took any of the following medications alone or in combination: sofosbuvir, simeprevir, daclatasvir, elbasvir, ledipasvir, glecaprevir, grazoprevir, voxilaprevir, ombitasvir, paritaprevir, ritonavir, dasabuvir, and/or velpatavir. Of note, although sofosbuvir became available for clinical use after its approval by the US Food and Drug Administration in December 2013, some of our patients had access to it before that as part of participation in clinical trials. Information was also obtained on whether patients achieved post-treatment SVR. Patients diagnosed with HCC before the year 2015 were included in other studies performed by this group (22,29,30). The database was managed centrally using the REDCap secure web application.

Determination of comorbidities and underlying HCC etiology
Chart documentation and/or laboratory confirmation was used to verify other comorbidities, including hypertension, diabetes mellitus, dyslipidemia, coronary artery disease, peripheral vascular disease, HIV, and history of alcohol abuse. Underlying HCC etiologies were classified as HCV, HBV, alcohol, NAFLD, autoimmune hepatitis, primary biliary cholangitis, primary sclerosing cholangitis, hemochromatosis, alphal antitrypsin deficiency, rare, and unclear/unknown. The rare disease category comprised amyloidosis, sarcoidosis, cardiac cirrhosis, drug-induced liver disease, and environmental exposure. HCC etiology was classified as unclear/unknown if no clear underlying chronic liver disease was identified or if there were insufficient data to make the diagnosis. The criteria for alcohol abuse were based on consumption of more than 3 drinks per day, documentation of alcoholism/ alcohol abuse in the records, history of alcoholic hepatitis, or participation in an alcohol abuse treatment program (31). The diagnosis of NAFLD was made on the basis of electronic medical record documentation of managing physician and/or presence of hepatic steatosis on radiology or histology without evidence of excessive alcohol use or alternative liver disease. For HCC cases with a combination of underlying viral hepatitis along with alcohol abuse, primary etiology of chronic liver disease was assigned as viral hepatitis.

Determination of cirrhotic and noncirrhotic status
HCC cases were divided into 4 categories based on the criteria developed by Mittal et al. (31) and validated by our group (22): category 1: level 1 evidence (very high probability) of no cirrhosis, confirmed by both histological and radiological evidence; category 2: level 2 evidence (high probability) of no cirrhosis, based on imaging and laboratory criteria in the absence of histology; category 3: confirmed cirrhosis, based on histological, imaging, clinical, or laboratory criteria; and category 4: unclassified, cirrhosis categories could not be delineated because of insufficient data. Based on the laboratory values, the model of end-stage liver disease score, fibrosis-4 score, and the aspartate aminotransferase-to-platelet ratio index were also calculated. For cirrhotic cases, information on any liver-related complications such as ascites, varices, hepatic encephalopathy, and spontaneous bacterial peritonitis since the date of HCC diagnosis was collected.

Statistical analysis
Categorical values were summarized using frequency and percentage and compared using the χ² test. Continuous variables were summarized using median and interquartile range and compared using the Wilcoxon rank sum test. Piecewise logistic regression was used to investigate the yearly trends of HCC based on a breakpoint analysis. Coinciding with DAA introduction, 2014 was chosen to be the break point year for the regression
Table 1. Characteristics of the patients with hepatocellular carcinoma

| Variable                          | Overall                | 2009–2013 N = 1,127 | 2014–2019 N = 1,496 | P value |
|-----------------------------------|------------------------|----------------------|---------------------|---------|
| Age (yr)                          | 62.0 (57.0, 69.0)      | 61.0 (56.0, 68.0)    | 63.0 (58.0, 69.0)   | <0.0001 |
| Male sex                          | 2,046 (78.0%)          | 881 (78.2%)          | 1,165 (77.9%)       | 0.86    |
| Race                              |                        |                      |                     |         |
| White                             | 2,009 (76.9%)          | 881 (78.7%)          | 1,128 (75.6%)       | 0.18    |
| Black                             | 427 (16.3%)            | 177 (15.8%)          | 250 (16.7%)         |         |
| Asian                             | 64 (2.4%)              | 23 (2.1%)            | 41 (2.7%)           |         |
| Other                             | 32 (1.2%)              | 13 (1.2%)            | 19 (1.3%)           |         |
| Unknown                           | 81 (3.1%)              | 26 (2.3%)            | 55 (3.7%)           |         |
| Hispanic ethnicity                | 81 (3.1%)              | 26 (2.3%)            | 55 (3.7%)           | 0.08    |
| Center a                          |                        |                      |                     |         |
| Atrium Health                     | 1,326 (50.6%)          | 523 (46.4%)          | 803 (53.7%)         | 0.0002  |
| IU                                | 1,297 (49.4%)          | 604 (53.6%)          | 693 (46.3%)         |         |
| BMI at HCC diagnosis              | 27.9 (24.3, 32.1)      | 27.8 (24.5, 31.9)    | 27.9 (24.3, 32.3)   | 0.94    |
| Obesity                           | 946 (36.5%)            | 396 (35.8%)          | 550 (37.0%)         | 0.56    |
| Diabetes                          | 969 (37.1%)            | 408 (36.3%)          | 561 (37.7%)         | 0.49    |
| Hypertension                      | 1,602 (61.3%)          | 680 (60.6%)          | 922 (61.8%)         | 0.50    |
| Dyslipidemia                      | 722 (27.6%)            | 259 (23.1%)          | 463 (31.1%)         | <0.0001 |
| Coronary artery disease           | 475 (18.2%)            | 211 (18.8%)          | 264 (17.7%)         | 0.48    |
| Peripheral vascular disease       | 290 (11.1%)            | 95 (8.5%)            | 195 (13.1%)         | 0.0002  |
| History of alcohol abuse          | 1,091 (42.4%)          | 508 (45.5%)          | 583 (40.0%)         | 0.0051  |
| HIV-positive                      | 33 (1.3%)              | 15 (1.3%)            | 18 (1.2%)           | 0.77    |
| Total bilirubin (mg/dL)           | 1.2 (0.8, 2.1)         | 1.4 (0.9, 2.2)       | 1.1 (0.7, 2.0)      | <0.0001 |
| Albumin (g/dL)                    | 3.3 (2.8, 3.7)         | 3.1 (2.7, 3.5)       | 3.4 (2.9, 3.8)      | <0.0001 |
| Platelets (K/cumm)                | 118.0 (78.0, 183.0)    | 111.0 (73.0, 169.5)  | 123.0 (84.0, 192.0) | <0.0001 |
| Creatinine (mg/dL)                | 0.9 (0.7, 1.1)         | 0.9 (0.7, 1.2)       | 0.9 (0.7, 1.1)      | 0.55    |
| INR                               | 1.2 (1.1, 1.3)         | 1.2 (1.1, 1.4)       | 1.2 (1.1, 1.3)      | 0.0025  |
| MELD score                        | 10.0 (8.0, 14.0)       | 11.0 (9.0, 14.0)     | 10.0 (8.0, 14.0)    | <0.0001 |
| Complications                     |                        |                      |                     |         |
| Ascites                           | 1,122 (42.8%)          | 583 (51.7%)          | 539 (36.0%)         | <0.0001 |
| Encephalopathy                    | 737 (28.1%)            | 380 (33.7%)          | 357 (23.9%)         | <0.0001 |
| Varices                           | 1,069 (40.8%)          | 503 (44.6%)          | 566 (37.8%)         | 0.0005  |
| Variable                | Overall      | 2009–2013 | 2014–2019 | P value |
|-------------------------|--------------|-----------|-----------|---------|
|                         |              | N = 1,127 | N = 1,496 |         |
| SBP                     | 96 (3.7%)    | 56 (5.0%) | 40 (2.7%) | 0.0019  |
| Portal vein thrombosis  | 529 (20.2%)  | 255 (22.6%) | 274 (18.3%) | 0.0065  |
| Other                   | 353 (13.5%)  | 236 (20.9%) | 117 (7.8%) | <0.0001 |
| No complications occurred | 593 (22.6%)  | 168 (14.9%) | 425 (28.4%) | <0.0001 |
| Information not available or N/A | 224 (8.5%)  | 82 (7.3%) | 142 (9.5%) | 0.0444  |
| Cirrhotic status        |              |           |           |         |
| Cirrhotic               | 2,288 (87.2%) | 1,001 (91.1%) | 1,287 (87.0%) | <0.0001 |
| Noncirrhotic            | 290 (11.1%)  | 98 (8.9%) | 192 (13.0%) |         |
| Unclassified            | 40 (1.5%)    | 28 (2.5%) | 12 (0.8%) |         |
| Missing entirely        | 5 (0.2%)     | 0 (0.0%) | 5 (0.3%) |         |
| Underlying etiology     |              |           |           |         |
| AIH/PBC/PSC             | 35 (1.3%)    | 11 (1.0%) | 24 (1.6%) | 0.07    |
| Alcohol alone           | 331 (12.6%)  | 158 (14.0%) | 173 (11.6%) |         |
| HBV + alcohol           | 21 (0.8%)    | 7 (0.6%) | 14 (0.9%) |         |
| HBV alone               | 87 (3.3%)    | 38 (3.4%) | 49 (3.3%) |         |
| HCA1ATD                 | 30 (1.1%)    | 18 (1.6%) | 12 (0.8%) |         |
| HCV + alcohol           | 686 (26.2%)  | 313 (27.8%) | 373 (24.9%) |         |
| HCV + HBV (+/− alcohol) | 37 (1.4%)    | 17 (1.5%) | 20 (1.3%) |         |
| HCV alone               | 698 (26.6%)  | 287 (25.5%) | 411 (27.5%) |         |
| NAFLD                   | 451 (17.2%)  | 178 (15.8%) | 273 (18.2%) |         |
| Rare etiologies         | 14 (0.5%)    | 8 (0.7%) | 6 (0.4%) |         |
| Unclear/unknown         | 233 (8.9%)   | 92 (8.2%) | 141 (9.4%) |         |

A1ATD, alpha-1-antitrypsin deficiency; AIH, autoimmune hepatitis; HBV, hepatitis B virus; BMI, body mass index; HCV, hepatitis C virus; HC, hemochromatosis; INR, international normalized ratio; IU, Indiana University; MELD, Model for End-Stage Liver Disease; N/A, not applicable; NAFLD, nonalcoholic fatty liver disease; PBC, primary biliary cholangitis; PSC, primary sclerosing cholangitis; SBP, spontaneous bacterial peritonitis.

*Categorical values were summarized using frequency and percentage, and continuous variables were summarized using median and interquartile range.
analysis. Years were then divided into 2 eras: the pre-DAA era from 2009 to 2013 and the DAA era from 2014 to 2019. Odds ratios (ORs) and 95% confidence intervals (CIs) are reported for the change in yearly odds of an HCC patient having a given etiology. A \( P \) value of less than 0.05 was defined as statistically significant. All analyses were performed using SAS software, version 9.4 (SAS Institute; Cary, NC).

RESULTS

Study population
A total of 2,623 HCC cases were identified from the year 2009 to 2019 (Table 1), with 1,127 cases diagnosed in the pre-DAA era (2009–2013) and 1,496 cases diagnosed in the DAA era (2014–2019). The mean age of patients at the time of HCC diagnosis was 62 years (interquartile range [IQR] = 57–69). Most of the cases were male individuals (78%) and White (77%). At the time of HCC diagnosis, 87% of the cases was cirrhotic, 37% was obese, and 37% had diabetes. In the entire cohort, HCV alone or in combination with alcohol was the most common underlying etiology of HCC (53%), followed by NAFLD (17%) and alcoholic liver disease (13%) (Table 1).

HCC trends by underlying liver etiology
Over the course of the 10-year study period, HCV remained the dominant liver disease associated with HCC, followed by NAFLD and alcohol (Figure 1). Using 2014 as a break point for the DAA era, a significant annual decline in HCV-HCC cases in the DAA era was observed (OR = 0.93, 95% CI 0.88–0.99, \( P = 0.019 \)) (Figure 2a). There were no significant changes in the trends of NAFLD-related, alcohol-related, or HBV-related HCC in the 2 eras (Figure 2b–e).

Trends in HCV treatment and response
Compared with the pre-DAA era, the percentage of patients with HCV who did not receive HCV therapy significantly decreased in the DAA era (59% vs 35%, \( P < 0.001 \)) (Table 2). DAA therapy was given to a total of 516 (36%) of 1,421 patients with HCV from both eras but at much higher rate in the post-DAA era (51% vs 17%, \( P < 0.0001 \)). The rates of SVR achieved were significantly higher in the patients diagnosed with HCC and treated for HCV in the DAA era (79% vs 64%, \( P < 0.0001 \)). Of note, 19% of cases with HCV still received interferon in the post-DAA era, probably reflecting early challenges in implementing DAA therapy in practice. There were no differences in types of HCV treatment received (DAA or interferon-based regimen) between noncirrhotic and cirrhotic HCV-HCC groups in the overall cohort (see Supplementary Data Table 1, http://links.lww.com/CTG/A715).

HCC trends by cirrhotic status
Of the 290 noncirrhotic HCC cases in the entire cohort, most of the cases (66%) were diagnosed in the DAA era. There was no change in the annual trends of noncirrhotic HCC cases in the pre-DAA era but an annual increase in noncirrhotic HCC cases was observed in the DAA era (OR 1.13, 95% CI 1.03–1.23, \( P = 0.0095 \)) (Figure 3). There was also a significant decline in cirrhotic HCC in the DAA era (OR 0.89, 95% CI 0.81–0.97, \( P = 0.0095 \)).

Trends of cirrhotic status of HCC by underlying liver disease
For HCV-HCC, 2 significant changes in trends of cirrhotic status were observed in the DAA era: annual decrease in cirrhotic cases (OR 0.92, 95% CI 0.86–0.98, \( P = 0.012 \)) and annual increase in noncirrhotic cases (OR 1.35, 95% CI 1.08–1.69, \( P = 0.009 \)) (Figure 4a). For NAFLD, an annual increase in cirrhotic cases in
the DAA era was observed (OR 1.10, 95% CI 1.01–1.19, \( P = 0.03 \)), whereas noncirrhotic NAFLD-HCC did not show significant change in trend (Figure 4b). There were no significant changes in trends of alcohol-related or HBV-related cirrhotic and non-cirrhotic HCC cases in either of the 2 eras (Figure 4c–e).

**Differences in HCC tumor characteristics between DAA and pre-DAA eras**

The mean tumor size at the time of HCC diagnosis was slightly larger in the DAA era compared with that in the pre-DAA era (3.7 cm vs 3.5 cm, \( P = 0.039 \)) (Table 3). There were significant

---

**Figure 2.** Patient breakdown of liver-associated diseases with hepatocellular carcinoma, 2009–2019. (a) hepatitis C (b) nonalcoholic fatty liver disease (c) alcohol (d) hepatitis B (e) unknown.
differences in the percentages of tumor differentiations levels between the 2 eras ($P = 0.0002$). In the DAA era, well-differentiated HCC was less frequent (25% vs 36%), whereas moderately differentiated HCC (54% vs 48%) and poorly differentiated HCC (20% vs 15%) were more frequent. There were no significant differences between the 2 eras in anatomic staging of lesions, number of HCC lesions, or tumors within the Milan criteria at the time of HCC diagnosis (Table 3). However, higher percentages of patients presented in Barcelona Clinic Liver Cancer stages A and B in the DAA era (50% vs 30%) vs the pre-DAA era ($P < 0.0001$).

**Trends of HCC treatment modalities utilization**

In the DAA era, more HCC cases underwent resection (14% vs 11%, $P = 0.013$) and less underwent transplantation (12% vs 15%, $P = 0.023$) (Table 4), corresponding to the increased number of noncirrhotic HCC cases during the same period. For HCV-HCC, rate of resection increased (3% vs 11%, $P = 0.0002$) and rate of

---

**Table 2.** HCV treatment regimens offered to patients with HCC and SVR, stratified according to DAA era

| Treatment              | 2009–2013 N = 617 | 2014–2019 N = 804 | $P$ value |
|------------------------|-------------------|-------------------|-----------|
| After                  | 81 (13.1%)        | 137 (17.1%)       | <0.0001   |
| Before                 | 145 (23.5%)       | 362 (45.0%)       |           |
| Not applicable*        | 391 (63.4%)       | 305 (37.9%)       |           |
| DAA                    | 107 (17.3%)       | 409 (50.9%)       | <0.0001   |
| Pegylated interferon   | 153 (24.8%)       | 156 (19.4%)       | 0.0151    |
| Ribavirin              | 159 (25.8%)       | 202 (25.2%)       | 0.79      |
| Unknown                | 32 (5.2%)         | 64 (8.0%)         | 0.0384    |
| No treatment received  | 366 (59.3%)       | 282 (35.1%)       | <0.0001   |
| SVR                    | 143 (64.1%)       | 391 (78.8%)       | <0.0001   |

DAA, Direct-acting antiviral; HCV, hepatitis C virus; HCC, hepatocellular carcinoma; SVR, sustained virological response.

*Patients who did not receive treatment, unknown treatment type, or patients who may have multiple treatments both before and after HCC diagnosis.

Note: The exact date of HCV treatment receipt relative to HCC diagnosis is not known because it could not be collected from the records of many patients.
transplantation decreased (19% vs 12%, \( P = 0.0006 \)) in the DAA era compared with the pre-DAA era. When comparing cirrhotic and noncirrhotic HCV-HCC cases, higher rates of resection and zero cases of transplantation were noted in noncirrhotic HCC group (Table S2). There were no differences in trends of utilization of liver-directed or ablative therapies between the 2 eras.

Decreased utilization of sorafenib was observed in the DAA era (13% vs 18%, \( P = 0.0002 \)) coinciding with an increase in
utilization of newer therapies for HCC such as nivolumab (categorized as other) (7% vs 4%, \( P = 0.0002 \)).

**Trends of cirrhosis-related complications**
The rates of hepatic complications including decompensation events and portal venous thrombosis in all cirrhotic HCC cases were significantly lower in the DAA era than in the pre-DAA era (Table 1). The same findings were observed when only cirrhotic HCV-HCC cases were assessed based on receipt of DAA (Table S3).

**DISCUSSION**
Although HCV remains the dominant liver disease associated with HCC, this study showed significant decline in the proportions of HCV-HCC cases since the introduction of DAA. Of importance, the overall noncirrhotic HCC cases increased whereas cirrhotic HCC cases decreased in the DAA era, mainly driven by similar trends in noncirrhotic and cirrhotic HCV-HCC in the same period. These changes were associated with increased utilization of resection and decreased utilization of liver transplantation for HCC treatment, also driven by similar changes in utilization of these treatment modalities for HCV-HCC in the DAA era.

The decline in HCC incidence in patients with HCV achieving SVR with DAA therapy is beginning to have an impact on the burden of HCV-HCC (12,15,18). This trend is associated with a change in the mix of cirrhotic and noncirrhotic HCV-HCC cases. The annual increase in noncirrhotic HCC cases in this study was largely driven by an increase in noncirrhotic HCV-HCC cases. There were no differences in the type or frequency of treatment for HCV (DAA or interferon-based) between noncirrhotic and cirrhotic HCV-HCC cases to suggest undertreatment of noncirrhotic cases causing their uptrend in the DAA era.

As expected, more cases with HCC received HCV therapy and achieved SVR in the DAA era. However, between 2014 and 2019, only 50% of cases with HCV were treated with DAAs, and the SVR rates achieved in this population (79%) were lower than SVR rates that exceed 90% in the non-HCC setting (7,8). This is consistent with the findings of a recent meta-analysis that showed a significant reduction in pooled SVR rate in patients with HCC compared with non-HCC patients and a large drop in SVR rate to 73% in cases with active HCC (32). These findings along with the continued use of interferon in the early DAA era reflect a transition phase to the newer therapeutic agents and highlight the early challenges of rapidly changing composition and duration of DAA combination regimens, practice patterns, and HCV patient’s selection for DAA therapy in that period (19,33,34).

Liver transplantation utilization decreased whereas resection for HCC increased in the DAA era in this study, driven by similar utilization trended for these modalities for HCV-HCC in the

---

**Table 3. Tumor characteristics in the DAA and Pre-DAA era**

| Variable                                      | 2009–2013 | 2014–2019 | \( P \) value |
|------------------------------------------------|-----------|-----------|---------------|
| Period                                        | N = 1,127 | N = 1,496 |               |
| Tumor size (cm)                               | 3.5 (2.2, 5.8) | 3.7 (2.4, 6.5) | 0.0385        |
| AFP category                                   |           |           |               |
| <20                                           | 506 (48.2%) | 738 (52.7%) | 0.05          |
| 20–200                                        | 224 (21.3%) | 292 (20.9%) |               |
| >200                                          | 320 (30.5%) | 370 (26.4%) |               |
| Tumor differentiation                         |           |           | 0.0002        |
| Well                                          | 189 (36.0%) | 171 (24.8%) |               |
| Moderate                                      | 251 (47.8%) | 370 (53.7%) |               |
| Poor                                          | 77 (14.7%)  | 139 (20.2%) |               |
| Undifferentiated/anaplastic                   | 8 (1.5%)   | 9 (1.3%)   |               |
| Anatomic stage category                       |           |           | 0.87          |
| Stage I or II                                 | 512 (66.3%) | 863 (66.0%) |               |
| Stage III or IV                               | 260 (33.7%) | 445 (34.0%) |               |
| Tumor stage                                   |           |           | 0.68          |
| Single                                        | 483 (43.0%) | 639 (43.0%) |               |
| 3 tumors \(<\) 3 cm                           | 139 (12.4%) | 168 (11.3%) |               |
| Large multinodular                             | 225 (20.0%) | 322 (21.7%) |               |
| Vascular invasion or extrahepatic spread      | 277 (24.6%) | 358 (24.1%) |               |
| Tumor within Milan criteria                   | 540 (48.0%) | 677 (45.5%) | 0.20          |
| BCLC stage                                    |           |           | <0.0001       |
| Stage A                                       | 171 (20.9%) | 528 (36.4%) |               |
| Stage B                                       | 76 (9.3%)   | 193 (13.3%) |               |
| Stage C                                       | 382 (46.6%) | 530 (36.5%) |               |
| Stage D                                       | 190 (23.2%) | 200 (13.8%) |               |

**American College of Gastroenterology**

**Table 3. Tumor characteristics in the DAA and Pre-DAA era**

**Clinical and Translational Gastroenterology**
same period. Other studies have yielded similar results indicating the positive impact of DAA in reducing model of end-stage liver disease score and decreased listing for and utilization of liver transplantation in HCV-HCC (35–37). Puighevi et al. recently described a 14.6% decrease in liver transplantation utilization for HCV-HCC in the DAA era (38). Recent studies have also noted an alarming trend of increased liver transplantation rates on NAFLD-HCC cases (39,40). But to our knowledge, no other study reported increasing resection rates for HCV-HCC in the DAA era.

We previously reported a downtrend in noncirrhotic HCC and an uptrend for cirrhotic HCC between 2000 and 2014 (22). As we moved into the DAA era in this study, these trends seem to flip with rising noncirrhotic HCC and declining cirrhotic HCC between 2014 and 2019. The new trends are mainly due to changes in cirrhotic and noncirrhotic HCV-HCC in the DAA era. Of importance, the earlier significant uptrend in cirrhotic NAFLD-HCC we observed between 2000 and 2014 has continued through 2019, highlighting the enlarging contribution of NAFLD to HCC burden. This is a particularly important trend and supports future projections for NAFLD overtaking HCV as the primary etiology of HCC in the DAA era (41,42).

This study has a few limitations. It was conducted at tertiary care centers, and its findings may not generalize to other practice settings. Owing to its retrospective nature, some data points were missing. We could not determine the trends of HCC related to autoimmune and rare etiologies because of the small numbers in our data set. Another limitation to our study is that it involved only 2 tertiary care centers where liver resection and transplant are available options for HCC treatment. This contrasts with nontransplant centers where resection, rather than transplant, may be used more as the locally available option to some patients with HCC. Furthermore, changing resection and transplant practices for HCC across different regions in the United States may limit the generalization of pattern of utilization for these modalities we observed in our study to the rest of the United States. The study also has several strengths. The 10-year study period helped us examine the trends of HCC at our 2 sites. With 5-year data available pre-2014 and post-2014, we were able to evaluate the impact of DAA therapy in its early years of introduction on trends of liver disease etiologies and cirrhotic status in cases with HCC. We collected detailed patient-level data that allowed ascertainment of underlying liver disease and cirrhotic status and assessment of changes in utilization of different HCC treatment modalities before and after DAAs introduction.

In conclusion, this study showed a significant decrease in HCV-HCC cases in the DAA era without change in the contribution of other liver disease to the overall burden of HCC. The new trends of increase in noncirrhotic-HCC and decrease in cirrhotic HCC in the DAA era were associated with increased utilization of resection and decreased utilization of liver transplantation for HCC treatment. How expanded access to and changing patterns of DAAs use in practice will further affect the contribution of HCV to the overall burden of HCC, proportions of noncirrhotic HCC, and utilization of HCC different treatment modalities will require further study.

**CONFLICTS OF INTEREST**

Guarantor of article: Samer Gawrieh, MD.

Specific author contributions: K.M.: data collection, data analysis, manuscript preparation, and manuscript revision. A.M., M.P., L.D.: data collection and manuscript revision. H.B., H.L.: data analysis and manuscript revision. L.N., N.C., A.D.: study design, data analysis and

| Table 4. Treatment modalities offered to patients with HCC, stratified according to DAA era |
|---------------------------------------------------------------|
| **Variable** | **Period** | **P**<sub>value</sub> |
| | **2009–2013** | **2014–2019** | **2014–2019** |
| **Treatment modalities** | | | |
| Resection | 121 (10.7%) | 209 (14.0%) | 0.0134 |
| Resection for those with HCV-related HCC | 33 (5.4%) | 87 (10.8%) | 0.0002 |
| Liver transplantation (all) | 170 (15.1%) | 180 (12.0%) | 0.0229 |
| Liver transplantation for those within Milan criteria | 139 (25.7%) | 146 (21.6%) | 0.09 |
| Liver transplantation for those with HCV-related HCC | 114 (18.5%) | 96 (11.9%) | 0.0006 |
| Catheter-delivered therapy | 555 (49.2%) | 701 (46.9%) | 0.23 |
| Sorafenib | 202 (17.9%) | 190 (12.7%) | 0.0002 |
| SBRT | 100 (8.9%) | 130 (8.7%) | 0.87 |
| RFA and/or microwave ablation | 183 (16.2%) | 271 (18.1%) | 0.21 |
| Palliative/Hospice care | 402 (35.7%) | 498 (33.3%) | 0.20 |
| Other | 40 (3.5%) | 103 (6.9%) | 0.0002 |
| None | 57 (5.1%) | 44 (2.9%) | 0.0053 |
| Unknown | 19 (1.7%) | 26 (1.7%) | 0.92 |

DAA, direct-acting antiviral; HCV, hepatitis C; HCC, hepatocellular carcinoma; RFA, radiofrequency ablation; SBRT, stereotactic body radiation therapy.
manuscript revision. S.G.: study design, data analysis, manuscript preparation and manuscript revision.

Financial support: Internal funds from the Division of Gastroenterology and Hepatology at Indiana University School of Medicine.

Potential competing interests: K. Mathur, A. Mazhar, M. Patel, L. Dakhoul, H. Heather Burney, H. Liu and L. Nephew have no conflicts of interest or financial disclosures. N. Chalasani has ongoing research support from Eli Lilly, Galectin Therapeutics, Intercept, and Exact Sciences. In the past 12 months, he has received consulting fees from Abbvie, Madrigal, Nusirt, Allergan, Siemens, Genentech, Zydus, La Jolla, Axcella, Forestis Labs, and Galectin Therapeutics. A. deLemos has served on an advisory board for Takeda Pharmaceuticals in the last 12 months. S. Gawrieh consulting: TransMedics, Pfizer. Research grant support: Cirius, Galmed, Viking, and Zydus.

Study Highlights

WHAT IS KNOWN

- Direct-acting antivirals (DAA) decrease hepatocellular carcinoma (HCC) risk in patients with hepatitis C virus (HCV).
- HCV and nonalcoholic fatty liver disease are leading causes of HCC in the United States.

WHAT IS NEW HERE

- A trend of increase in noncirrhotic HCC and decrease in cirrhotic HCC was observed in the DAA era (following the year 2014).
- A driving factor is similar increase in noncirrhotic HCC and decrease in cirrhotic HCV-HCC in the DAA era.
- The rise in cirrhotic nonalcoholic fatty liver disease-HCC observed in the pre-DAA era continued in the DAA era.
- Rates of resection increased whereas utilization of transplantation for HCC decreased in the DAA era.

REFERENCES

1. Yang JD, Hainaut P, Gores GJ, et al. A global view of hepatocellular carcinoma: Trends, risk, prevention and management. Nat Rev Gastroenterol Hepatol 2019;16(10):589–604.

2. White DL, Thrift AP, Kanwal F, et al. Incidence of hepatocellular carcinoma in all 50 United States, from 2000 through 2012. Gastroenterology 2017;152(4):812–20.e5.

3. Akinyemiju T, Abersa S, Ahmad M, et al; Global Burden of Disease Liver Cancer Collaboration. The burden of primary liver cancer and underlying etiologies from 1990 to 2015 at the global, regional, and National level: Results from the global burden of disease study 2015. JAMA Oncol 2017; 3(12):1683–91.

4. Foreman KJ, Marquez N, Dolgert A, et al. Forecasting life expectancy, years of life lost, and all-cause and cause-specific mortality for 250 causes of death: Reference and alternative scenarios for 2016–40 for 195 countries and territories. Lancet 2018;392(10159):2052–90.

5. El-Serag HB. Epidemiology of viral hepatitis and hepatocellular carcinoma. Gastroenterology 2012;142(6):1264–73.e1.

6. Fattovich G, Stroffolini T, Zagni I, et al. Hepatocellular carcinoma in cirrhosis: Incidence and risk factors. Gastroenterology 2004;127(5 Suppl 1):S35–S50.

7. Falade-Nwulia O, et al. Oral direct-acting agent therapy for hepatitis C virus infection: A systematic review. Ann Intern Med 2017;166(9):637–48.

8. Verna EC, Morelli G, Terrault NA, et al. DAA therapy and long-term hepatic function in advanced/decompensated cirrhosis: Real-world experience from HCV-TARGET cohort. J Hepatol 2020;73(3):540–8.

9. Roche B, Coilly A, Duclos-Vallee JC, et al. The impact of treatment of hepatitis C with DAAAs on the occurrence of HCC. Liver Int 2018;38(Suppl 1):139–45.

10. Kanwal F, Kramer JR, Asch SM, et al. Long-Term risk of hepatocellular carcinoma in HCV patients treated with direct acting antiviral agents. Hepatology 2020;71(1):44–55.

11. Westbrook RH, Dushkego H. Natural history of hepatocellular carcinoma. J Hepatol 2014;61(1 Suppl):S58–S68.

12. Piñero F, Mendizabal M, Ridruejo E, et al. Treatment with direct-acting antivirals for HCV decreases but does not eliminate the risk of hepatocellular carcinoma. Liver Int 2019;39(6):1033–43.

13. Sangiovanni A, Alimenti E, Gattai R, et al. Undefined/non-malignant hepatic nodules are associated with early occurrence of HCC in DAA-treated patients with HCV-related cirrhosis. J Hepatol 2020;73(3):593–602.

14. Degasperi E, D’Ambrosio R, Iavarone M, et al. Factors associated with increased risk of de novo or recurrent hepatocellular carcinoma in patients with cirrhosis treated with direct-acting antivirals for HCV infection. Clin Gastroenterol Hepatol 2019;17(6):1183–91.e7.

15. Kanwal F, Kramer J, Asch SM, et al. Risk of hepatocellular cancer in HCV patients treated with direct-acting antiviral agents. Gastroenterology 2017;153(4):996–1005.e1.

16. Ioannou GN, Green PK, Berry K. HCV eradication induced by direct-acting antiviral agents reduces the risk of hepatocellular carcinoma. J Hepatol 2018;68(1):25–32.

17. Romano A, Angeli P, Piovesan S, et al. Newly diagnosed hepatocellular carcinoma in patients with advanced hepatitis C treated with DAAAs: A prospective population study. J Hepatol 2018;69(2):345–52.

18. Calvaruso V, Cabibbo G, Cacciola I, et al. Incidence of hepatocellular carcinoma in patients with HCV-associated cirrhosis treated with direct-acting antiviral agents. Gastroenterology 2018;155(2):411–21.e4.

19. Singal AG, Lim JK, Kanwal F. AGA clinical practice update on interaction between oral direct-acting antivirals for chronic hepatitis C infection and hepatocellular carcinoma: Expert review. Gastroenterology 2019;156(8):2149–57.

20. Kim HS, El-Serag HB. The epidemiology of hepatocellular carcinoma in the USA. Curr Gastroenterol Rep 2019;21(4):17.

21. Younossi ZM, Ongsoumen M, Henry L, et al. Association of nonalcoholic fatty liver disease (NAFLD) with hepatocellular carcinoma (HCC) in the USA. Curr Gastroenterol Rep 2019;21(4):17.

22. Younossi Z, Anstee QM, Marietti M, et al. Global burden of NAFLD and NASH: Trends, predictions, risk factors and prevention. Nat Rev Gastroenterol Hepatol 2018;15(1):11–20.

23. von Elm E, et al. The strengthening the reporting of observational studies in epidemiology (STROBE) statement: Guidelines for reporting observational studies. Int J Surg 2014;12(12):1495–9.

24. Marrero JA, Kulik LM, Sirlin CB, et al. Diagnosis, staging, and management of hepatocellular carcinoma: 2018 practice guidance by the American association for the study of liver diseases. Hepatology 2018;68(2):723–30.

25. Edge SB, Compton CC. The American joint committee on cancer: The 7th edition of the AJCC cancer staging manual and the future of TNM. Ann Surg Oncol 2010;17(6):1471–4.

26. Mazzaferrero V, Regalia E, Doci R, et al. Liver transplantation for the treatment of small hepatocellular carcinomas in patients with cirrhosis. N Engl J Med 1996;334(11):693–9.

27. Llovet JM, Bru C, Bruix J. Prognosis of hepatocellular carcinoma: The BCLC staging classification. Semin Liver Dis 1999;19(3):329–38.

28. DeLemos AS, Patel M, Gawrieh S, et al. Distinctive features and outcomes of hepatocellular carcinoma (HCC) in patients with alcohol-related liver disease: A United States multicenter study. Clin Transl Gastroenterol 2019;11:e00139.

29. Phipps M, Livanos A, Guo A, et al. Gender matters: Characteristics of hepatocellular carcinoma in women from a large, Multicenter Study in the United States. Am J Gastroenterol 2020;115(9):1486–95.

30. Mittal S, El-Serag HB, Sada YH, et al. Hepatocellular carcinoma in the absence of cirrhosis in United States veterans is associated with nonalcoholic fatty liver disease. Clin Gastroenterol Hepatol 2016;14(1):124–31.e1.

31. Ji F, Yeo YH, Wei MT, et al. Sustained virologic response to direct-acting antiviral therapy in patients with chronic hepatitis C and hepatocellular...
33. AASLD-IDSA HCV Guidance Panel. Hepatitis C Guidance 2018 Update: AASLD-IDSA Recommendations for Testing, Managing, and Treating Hepatitis C Virus Infection. Clin Infect Dis. 2018 Oct 30;67(10):1477–1492.
34. Rich NE, Yang JD, Perumalswami PV, et al. Provider attitudes and practice patterns for direct-acting antiviral therapy for patients with hepatocellular carcinoma. Clin Gastroenterol Hepatol 2020;18(4):974–83.
35. Vaziri A, Gimson A, Agarwal K, et al. Liver transplant listing for hepatitis C-associated cirrhosis and hepatocellular carcinoma has fallen in the United Kingdom since the introduction of direct-acting antiviral therapy. J Viral Hepat 2019;26(2):231–5.
36. Cholankeril G, Ahmed A. Alcoholic liver disease replaces hepatitis C virus infection as the leading indication for liver transplantation in the United States. Clin Gastroenterol Hepatol 2018;16(8):1356–8.
37. Bittermann T, Reddy KR. In the era of direct-acting antivirals, liver transplant delisting due to clinical improvement for hepatitis C remains infrequent. Clin Gastroenterol Hepatol 2020;S1542-3565(20)31294-5.
38. Puigvehi M, et al Liver transplant for hepatocellular carcinoma in the United States: Evolving trends over the last 3 decades. Am J Transpl 2020;20(1):220–30.
39. Younossi Z, Stepanova M, Ong JP, et al. Nonalcoholic steatohepatitis is the fastest growing cause of hepatocellular carcinoma in liver transplant candidates. Clin Gastroenterol Hepatol 2019;17(4):748–55.e3.
40. Haldar D, Kern B, Hodson J, et al. Outcomes of liver transplantation for non-alcoholic steatohepatitis: A European liver transplant registry study. J Hepatol 2019;71(2):313–22.
41. Huang DQ, El-Serag HB, Loomba R. Global epidemiology of NAFLD-related HCC: Trends, predictions, risk factors and prevention. Nat Rev Gastroenterol Hepatol 2020.
42. Younossi ZM, Stepanova M, Ong J, et al. Nonalcoholic steatohepatitis is the most rapidly increasing indication for liver transplantation in the United States. Clin Gastroenterol Hepatol 2021;19(3):580–89.e5.

Open Access This is an open access article distributed under the Creative Commons Attribution License 4.0 (CCBY), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.